Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Vir Biotechnology, Inc.VIR · Entity 4522 | EVP, Research & CSO | August 09, 2022 | August 10, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Vir Biotechnology, Inc.
Report date August 09, 2022 · Filed August 10, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 262,500 |
Ending reported balance
After 2022-08-09 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2022-08-09 · Exercise / conversion · Acquired 70,177 · Balance 254,584 Row 2 · 2022-08-09 · Exercise / conversion · Acquired 7,916 · Balance 262,500 |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.53 · Expires 2028-01-26 | Direct | 140,328 |
Reported balance
After 2022-08-09 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2022-08-09 · Exercise / conversion · Disposed 70,177 · Balance 140,328 F1: The option is fully vested and exercisable. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.40 · Expires 2029-07-12 | Direct | 125,416 |
Reported balance
After 2022-08-09 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2022-08-09 · Exercise / conversion · Disposed 7,916 · Balance 125,416 F2: 1/4 of the shares subject to the stock option vested and become exercisable on July 12, 2020, and the remaining shares will vest in 36 equal monthly installments thereafter. |
Filing footnotes · ownership attribution and instrument terms
F1: The option is fully vested and exercisable.
F2: 1/4 of the shares subject to the stock option vested and become exercisable on July 12, 2020, and the remaining shares will vest in 36 equal monthly installments thereafter.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 21, 2021 Filed Sep 22, 2021 23:34 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | Exercise / conversionCommon Stock | 4,125 | $1.53 | $6,311.25 |
DisclosureSEC source: 0001209191-21-057317 · doc4.xml · nonDerivative · entry 1 Virgin Herbert · CIK 0001786378 · EVP, Research & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 103,825 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 07, 2021 Filed Sep 9, 2021 20:59 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | Exercise / conversionStock Option (Right to Buy) · Derivative | 4,125 | $0.00 Strike: $1.53 | $0.00 |
DisclosureSEC source: 0001209191-21-055311 · doc4.xml · derivative · entry 4 Virgin Herbert · CIK 0001786378 · EVP, Research & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 263,255 Underlying: Common Stock · 4,125 shares Expires 2028-01-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: 1/4 of the shares subject to the stock option vested and became exercisable on January 8, 2019, and the remaining shares vest in 36 equal monthly installments thereafter. Read SEC document |
| September 07, 2021 Filed Sep 9, 2021 20:59 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | SaleCommon Stock | 2,750 | $50.00 | $137,500.00 |
DisclosureSEC source: 0001209191-21-055311 · doc4.xml · nonDerivative · entry 3 Virgin Herbert · CIK 0001786378 · EVP, Research & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 99,700 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 26, 2021. Read SEC document |
| September 07, 2021 Filed Sep 9, 2021 20:59 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | SaleCommon Stock | 1,375 | $49.00 | $67,375.00 |
DisclosureSEC source: 0001209191-21-055311 · doc4.xml · nonDerivative · entry 2 Virgin Herbert · CIK 0001786378 · EVP, Research & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 102,450 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 26, 2021. Read SEC document |
| September 07, 2021 Filed Sep 9, 2021 20:59 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | Exercise / conversionCommon Stock | 4,125 | $1.53 | $6,311.25 |
DisclosureSEC source: 0001209191-21-055311 · doc4.xml · nonDerivative · entry 1 Virgin Herbert · CIK 0001786378 · EVP, Research & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 103,825 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 25, 2021 Filed Aug 27, 2021 00:46 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,750 | $0.00 Strike: $1.53 | $0.00 |
DisclosureSEC source: 0001209191-21-053560 · doc4.xml · derivative · entry 3 Virgin Herbert · CIK 0001786378 · EVP, Research & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 267,380 Underlying: Common Stock · 2,750 shares Expires 2028-01-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: 1/4 of the shares subject to the stock option vested and became exercisable on January 8, 2019, and the remaining shares vest in 36 equal monthly installments thereafter. Read SEC document |
| August 25, 2021 Filed Aug 27, 2021 00:46 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | SaleCommon Stock | 2,750 | $50.00 | $137,500.00 |
DisclosureSEC source: 0001209191-21-053560 · doc4.xml · nonDerivative · entry 2 Virgin Herbert · CIK 0001786378 · EVP, Research & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 99,700 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 26, 2021. Read SEC document |
| August 25, 2021 Filed Aug 27, 2021 00:46 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | Exercise / conversionCommon Stock | 2,750 | $1.53 | $4,207.50 |
DisclosureSEC source: 0001209191-21-053560 · doc4.xml · nonDerivative · entry 1 Virgin Herbert · CIK 0001786378 · EVP, Research & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 102,450 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 24, 2021 Filed Aug 25, 2021 21:00 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,375 | $0.00 Strike: $1.53 | $0.00 |
DisclosureSEC source: 0001209191-21-053331 · doc4.xml · derivative · entry 3 Virgin Herbert · CIK 0001786378 · EVP, Research & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 270,130 Underlying: Common Stock · 1,375 shares Expires 2028-01-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: 1/4 of the shares subject to the stock option vested and became exercisable on January 8, 2019, and the remaining shares vest in 36 equal monthly installments thereafter. Read SEC document |
| August 24, 2021 Filed Aug 25, 2021 21:00 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | SaleCommon Stock | 1,375 | $48.00 | $66,000.00 |
DisclosureSEC source: 0001209191-21-053331 · doc4.xml · nonDerivative · entry 2 Virgin Herbert · CIK 0001786378 · EVP, Research & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 99,700 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on April 14, 2020. Read SEC document |
| August 24, 2021 Filed Aug 25, 2021 21:00 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | Exercise / conversionCommon Stock | 1,375 | $1.53 | $2,103.75 |
DisclosureSEC source: 0001209191-21-053331 · doc4.xml · nonDerivative · entry 1 Virgin Herbert · CIK 0001786378 · EVP, Research & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 101,075 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 23, 2021 Filed Aug 24, 2021 22:44 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | Exercise / conversionStock Option (Right to Buy) · Derivative | 13,750 | $0.00 Strike: $1.53 | $0.00 |
DisclosureSEC source: 0001209191-21-053236 · doc4.xml · derivative · entry 3 Virgin Herbert · CIK 0001786378 · EVP, Research & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 271,505 Underlying: Common Stock · 13,750 shares Expires 2028-01-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: 1/4 of the shares subject to the stock option vested and became exercisable on January 8, 2019, and the remaining shares vest in 36 equal monthly installments thereafter. Read SEC document |
| August 23, 2021 Filed Aug 24, 2021 22:44 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | SaleCommon Stock | 13,750 | $50.00 | $687,500.00 |
DisclosureSEC source: 0001209191-21-053236 · doc4.xml · nonDerivative · entry 2 Virgin Herbert · CIK 0001786378 · EVP, Research & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 99,700 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on April 14, 2020. Read SEC document |
| August 23, 2021 Filed Aug 24, 2021 22:44 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | Exercise / conversionCommon Stock | 13,750 | $1.53 | $21,037.50 |
DisclosureSEC source: 0001209191-21-053236 · doc4.xml · nonDerivative · entry 1 Virgin Herbert · CIK 0001786378 · EVP, Research & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 113,450 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 10, 2021 Filed Aug 11, 2021 21:00 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,375 | $0.00 Strike: $1.53 | $0.00 |
DisclosureSEC source: 0001209191-21-050905 · doc4.xml · derivative · entry 3 Virgin Herbert · CIK 0001786378 · EVP, Research & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 285,255 Underlying: Common Stock · 1,375 shares Expires 2028-01-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: 1/4 of the shares subject to the stock option vested and became exercisable on January 8, 2019, and the remaining shares vest in 36 equal monthly installments thereafter. Read SEC document |
| August 10, 2021 Filed Aug 11, 2021 21:00 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | SaleCommon Stock | 1,375 | $41.00 | $56,375.00 |
DisclosureSEC source: 0001209191-21-050905 · doc4.xml · nonDerivative · entry 2 Virgin Herbert · CIK 0001786378 · EVP, Research & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 99,700 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on April 14, 2020. Read SEC document |
| August 10, 2021 Filed Aug 11, 2021 21:00 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | Exercise / conversionCommon Stock | 1,375 | $1.53 | $2,103.75 |
DisclosureSEC source: 0001209191-21-050905 · doc4.xml · nonDerivative · entry 1 Virgin Herbert · CIK 0001786378 · EVP, Research & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 101,075 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 27, 2021 Filed Jul 28, 2021 23:34 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,375 | $0.00 Strike: $1.53 | $0.00 |
DisclosureSEC source: 0001209191-21-048466 · doc4.xml · derivative · entry 3 Virgin Herbert · CIK 0001786378 · EVP, Research & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 286,630 Underlying: Common Stock · 1,375 shares Expires 2028-01-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: 1/4 of the shares subject to the stock option vested and became exercisable on January 8, 2019, and the remaining shares vest in 36 equal monthly installments thereafter. Read SEC document |
| July 27, 2021 Filed Jul 28, 2021 23:34 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | SaleCommon Stock | 1,375 | $36.72 | $50,490.00 |
DisclosureSEC source: 0001209191-21-048466 · doc4.xml · nonDerivative · entry 2 Virgin Herbert · CIK 0001786378 · EVP, Research & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 99,700 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on April 14, 2020. Read SEC document |
| July 27, 2021 Filed Jul 28, 2021 23:34 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | Exercise / conversionCommon Stock | 1,375 | $1.53 | $2,103.75 |
DisclosureSEC source: 0001209191-21-048466 · doc4.xml · nonDerivative · entry 1 Virgin Herbert · CIK 0001786378 · EVP, Research & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 101,075 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 13, 2021 Filed Jul 14, 2021 21:46 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,375 | $0.00 Strike: $1.53 | $0.00 |
DisclosureSEC source: 0001209191-21-046688 · doc4.xml · derivative · entry 3 Virgin Herbert · CIK 0001786378 · EVP, Research & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 288,005 Underlying: Common Stock · 1,375 shares Expires 2028-01-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: 1/4 of the shares subject to the stock option vested and became exercisable on January 8, 2019, and the remaining shares vest in 36 equal monthly installments thereafter. Read SEC document |
| July 13, 2021 Filed Jul 14, 2021 21:46 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | SaleCommon Stock | 1,375 | $36.72 | $50,490.00 |
DisclosureSEC source: 0001209191-21-046688 · doc4.xml · nonDerivative · entry 2 Virgin Herbert · CIK 0001786378 · EVP, Research & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 99,700 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on April 14, 2020. Read SEC document |
| July 13, 2021 Filed Jul 14, 2021 21:46 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | Exercise / conversionCommon Stock | 1,375 | $1.53 | $2,103.75 |
DisclosureSEC source: 0001209191-21-046688 · doc4.xml · nonDerivative · entry 1 Virgin Herbert · CIK 0001786378 · EVP, Research & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 101,075 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 29, 2021 Filed Jun 30, 2021 23:59 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,375 | $0.00 Strike: $1.53 | $0.00 |
DisclosureSEC source: 0001209191-21-044166 · doc4.xml · derivative · entry 3 Virgin Herbert · CIK 0001786378 · EVP, Research & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 289,380 Underlying: Common Stock · 1,375 shares Expires 2028-01-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: 1/4 of the shares subject to the stock option vested and became exercisable on January 8, 2019, and the remaining shares vest in 36 equal monthly installments thereafter. Read SEC document |
| June 29, 2021 Filed Jun 30, 2021 23:59 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | SaleCommon Stock | 1,375 | $46.63 | $64,116.25 |
DisclosureSEC source: 0001209191-21-044166 · doc4.xml · nonDerivative · entry 2 Virgin Herbert · CIK 0001786378 · EVP, Research & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 99,700 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on April 14, 2020. Read SEC document |
| June 29, 2021 Filed Jun 30, 2021 23:59 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | Exercise / conversionCommon Stock | 1,375 | $1.53 | $2,103.75 |
DisclosureSEC source: 0001209191-21-044166 · doc4.xml · nonDerivative · entry 1 Virgin Herbert · CIK 0001786378 · EVP, Research & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 101,075 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 23, 2021 Filed Jun 24, 2021 20:36 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | Exercise / conversionStock Option (Right to Buy) · Derivative | 8,000 | $0.00 Strike: $1.53 | $0.00 |
DisclosureSEC source: 0001209191-21-043032 · doc4.xml · derivative · entry 2 Virgin Herbert · CIK 0001786378 · EVP, Research & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 290,755 Underlying: Common Stock · 8,000 shares Expires 2028-01-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: 1/4 of the shares subject to the stock option vested and became exercisable on January 8, 2019, and the remaining shares vest in 36 equal monthly installments thereafter. Read SEC document |
| June 23, 2021 Filed Jun 24, 2021 20:36 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | Exercise / conversionCommon Stock | 8,000 | $1.53 | $12,240.00 |
DisclosureSEC source: 0001209191-21-043032 · doc4.xml · nonDerivative · entry 1 Virgin Herbert · CIK 0001786378 · EVP, Research & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 99,700 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 15, 2021 Filed Jun 17, 2021 21:03 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,375 | $0.00 Strike: $1.53 | $0.00 |
DisclosureSEC source: 0001209191-21-041514 · doc4.xml · derivative · entry 3 Virgin Herbert · CIK 0001786378 · EVP, Research & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 298,755 Underlying: Common Stock · 1,375 shares Expires 2028-01-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: 1/4 of the shares subject to the stock option vested and became exercisable on January 8, 2019, and the remaining shares vest in 36 equal monthly installments thereafter. Read SEC document |
| June 15, 2021 Filed Jun 17, 2021 21:03 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | SaleCommon Stock | 1,375 | $45.29 | $62,273.75 |
DisclosureSEC source: 0001209191-21-041514 · doc4.xml · nonDerivative · entry 2 Virgin Herbert · CIK 0001786378 · EVP, Research & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 91,700 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on April 14, 2020. Read SEC document |
| June 15, 2021 Filed Jun 17, 2021 21:03 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | Exercise / conversionCommon Stock | 1,375 | $1.53 | $2,103.75 |
DisclosureSEC source: 0001209191-21-041514 · doc4.xml · nonDerivative · entry 1 Virgin Herbert · CIK 0001786378 · EVP, Research & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 93,075 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 01, 2021 Filed Jun 2, 2021 21:38 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,375 | $0.00 Strike: $1.53 | $0.00 |
DisclosureSEC source: 0001209191-21-037342 · doc4.xml · derivative · entry 3 Virgin Herbert · CIK 0001786378 · EVP, Research & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 300,130 Underlying: Common Stock · 1,375 shares Expires 2028-01-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: 1/4 of the shares subject to the stock option vested and became exercisable on January 8, 2019, and the remaining shares vest in 36 equal monthly installments thereafter. Read SEC document |
| June 01, 2021 Filed Jun 2, 2021 21:38 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | SaleCommon Stock | 1,375 | $42.51 | $58,451.25 |
DisclosureSEC source: 0001209191-21-037342 · doc4.xml · nonDerivative · entry 2 Virgin Herbert · CIK 0001786378 · EVP, Research & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 91,700 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on April 14, 2020. Read SEC document |
| June 01, 2021 Filed Jun 2, 2021 21:38 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | Exercise / conversionCommon Stock | 1,375 | $1.53 | $2,103.75 |
DisclosureSEC source: 0001209191-21-037342 · doc4.xml · nonDerivative · entry 1 Virgin Herbert · CIK 0001786378 · EVP, Research & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 93,075 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 18, 2021 Filed May 19, 2021 20:39 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,375 | $0.00 Strike: $1.53 | $0.00 |
DisclosureSEC source: 0001209191-21-034017 · doc4.xml · derivative · entry 3 Virgin Herbert · CIK 0001786378 · EVP, Research & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 301,505 Underlying: Common Stock · 1,375 shares Expires 2028-01-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: 1/4 of the shares subject to the stock option vested and became exercisable on January 8, 2019, and the remaining shares vest in 36 equal monthly installments thereafter. Read SEC document |
| May 18, 2021 Filed May 19, 2021 20:39 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | SaleCommon Stock | 1,375 | $45.03 | $61,916.25 |
DisclosureSEC source: 0001209191-21-034017 · doc4.xml · nonDerivative · entry 2 Virgin Herbert · CIK 0001786378 · EVP, Research & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 91,700 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on April 14, 2020. Read SEC document |
| May 18, 2021 Filed May 19, 2021 20:39 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | Exercise / conversionCommon Stock | 1,375 | $1.53 | $2,103.75 |
DisclosureSEC source: 0001209191-21-034017 · doc4.xml · nonDerivative · entry 1 Virgin Herbert · CIK 0001786378 · EVP, Research & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 93,075 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 04, 2021 Filed May 5, 2021 23:36 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,375 | $0.00 Strike: $1.53 | $0.00 |
DisclosureSEC source: 0001209191-21-030485 · doc4.xml · derivative · entry 3 Virgin Herbert · CIK 0001786378 · EVP, Research & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 302,880 Underlying: Common Stock · 1,375 shares Expires 2028-01-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: 1/4 of the shares subject to the stock option vested and became exercisable on January 8, 2019, and the remaining shares vest in 36 equal monthly installments thereafter. Read SEC document |
| May 04, 2021 Filed May 5, 2021 23:36 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | SaleCommon Stock | 1,375 | $46.03 | $63,291.25 |
DisclosureSEC source: 0001209191-21-030485 · doc4.xml · nonDerivative · entry 2 Virgin Herbert · CIK 0001786378 · EVP, Research & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 91,700 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on April 14, 2020. Read SEC document |
| May 04, 2021 Filed May 5, 2021 23:36 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | Exercise / conversionCommon Stock | 1,375 | $1.53 | $2,103.75 |
DisclosureSEC source: 0001209191-21-030485 · doc4.xml · nonDerivative · entry 1 Virgin Herbert · CIK 0001786378 · EVP, Research & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 93,075 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 27, 2021 Filed Apr 28, 2021 20:41 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | Exercise / conversionStock Option (Right to Buy) · Derivative | 7,900 | $0.00 Strike: $1.53 | $0.00 |
DisclosureSEC source: 0001209191-21-028811 · doc4.xml · derivative · entry 3 Virgin Herbert · CIK 0001786378 · EVP, Research & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 304,255 Underlying: Common Stock · 7,900 shares Expires 2028-01-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: 1/4 of the shares subject to the stock option vested and became exercisable on January 8, 2019, and the remaining shares vest in 36 equal monthly installments thereafter. Read SEC document |
| April 27, 2021 Filed Apr 28, 2021 20:41 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | SaleCommon Stock | 7,900 | $49.50 | $391,076.86 |
DisclosureSEC source: 0001209191-21-028811 · doc4.xml · nonDerivative · entry 2 Virgin Herbert · CIK 0001786378 · EVP, Research & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 91,700 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on April 14, 2020. F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $49.4546 to $49.5295 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| April 27, 2021 Filed Apr 28, 2021 20:41 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | Exercise / conversionCommon Stock | 7,900 | $1.53 | $12,087.00 |
DisclosureSEC source: 0001209191-21-028811 · doc4.xml · nonDerivative · entry 1 Virgin Herbert · CIK 0001786378 · EVP, Research & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 99,600 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 19, 2021 Filed Apr 20, 2021 22:18 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,340 | $0.00 Strike: $1.53 | $0.00 |
DisclosureSEC source: 0001209191-21-027614 · doc4.xml · derivative · entry 3 Virgin Herbert · CIK 0001786378 · EVP, Research & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 312,155 Underlying: Common Stock · 2,340 shares Expires 2028-01-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: 1/4 of the shares subject to the stock option vested and became exercisable on January 8, 2019, and the remaining shares vest in 36 equal monthly installments thereafter. Read SEC document |
| April 19, 2021 Filed Apr 20, 2021 22:18 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | SaleCommon Stock | 2,340 | $48.00 | $112,320.00 |
DisclosureSEC source: 0001209191-21-027614 · doc4.xml · nonDerivative · entry 2 Virgin Herbert · CIK 0001786378 · EVP, Research & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 91,700 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on April 14, 2020. Read SEC document |
| April 19, 2021 Filed Apr 20, 2021 22:18 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | Exercise / conversionCommon Stock | 2,340 | $1.53 | $3,580.20 |
DisclosureSEC source: 0001209191-21-027614 · doc4.xml · nonDerivative · entry 1 Virgin Herbert · CIK 0001786378 · EVP, Research & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 94,040 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 16, 2021 Filed Apr 20, 2021 00:00 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | Exercise / conversionStock Option (Right to Buy) · Derivative | 3,500 | $0.00 Strike: $1.53 | $0.00 |
DisclosureSEC source: 0001209191-21-027425 · doc4.xml · derivative · entry 2 Virgin Herbert · CIK 0001786378 · EVP, Research & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 314,495 Underlying: Common Stock · 3,500 shares Expires 2028-01-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: 1/4 of the shares subject to the stock option vested and became exercisable on January 8, 2019, and the remaining shares vest in 36 equal monthly installments thereafter. Read SEC document |
| April 16, 2021 Filed Apr 20, 2021 00:00 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | Exercise / conversionCommon Stock | 3,500 | $1.53 | $5,355.00 |
DisclosureSEC source: 0001209191-21-027425 · doc4.xml · nonDerivative · entry 1 Virgin Herbert · CIK 0001786378 · EVP, Research & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 91,700 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 13, 2021 Filed Apr 15, 2021 21:36 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | Exercise / conversionStock Option (Right to Buy) · Derivative | 5,560 | $0.00 Strike: $1.53 | $0.00 |
DisclosureSEC source: 0001209191-21-026858 · doc4.xml · derivative · entry 3 Virgin Herbert · CIK 0001786378 · EVP, Research & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 317,995 Underlying: Common Stock · 5,560 shares Expires 2028-01-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: 1/4 of the shares subject to the stock option vested and became exercisable on January 8, 2019, and the remaining shares vest in 36 equal monthly installments thereafter. Read SEC document |
| April 13, 2021 Filed Apr 15, 2021 21:36 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | SaleCommon Stock | 5,560 | $43.57 | $242,244.20 |
DisclosureSEC source: 0001209191-21-026858 · doc4.xml · nonDerivative · entry 2 Virgin Herbert · CIK 0001786378 · EVP, Research & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 88,200 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on April 14, 2020. F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.5286 to $43.6146 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.